Summary
Rachel is a Senior Lecturer in Medical Statistics and Clinical Trials at Imperial College London, and co-head of Statistics at Imperial Clinical Trials Unit (ICTU), School of Public Health.
Rachel has worked in the area of clinical trials for over 10 years and has a broad range of experience in the design and analysis of clinical trials.
Rachel's methodological research interests focus on the reporting and analysis of adverse events in clinical trials and the development of statistical methods to better identify adverse reactions. She is recognised both nationally and internationally for her work in this area and co-leads a harms theme for the MRC-NIHR Trials Methodology Research Partnership Outcomes Working Group.
Rachel obtained a BSc in Mathematics from the University of Nottingham in 2008 and was awarded an NIHR Research Methods Fellowship to complete her MSc in Medical Statistics at the London School of Hygiene and Tropical Medicine in 2009, after which she spent two years working as a statistician at the Institute of Psychiatry, Psychology and Neuroscience, King’s College London. In 2012 Rachel moved to Singapore to work for an academic clinical research organisation focusing on clinical trials in infectious diseases and mental health. She joined the Division of Health and Social Care Research, King’s College London in 2015 as a research fellow to work as a clinical trial statistician including both early and later phase trials. During this time she also worked as a general adviser for the NIHR Research Design Service. Rachel was awarded an NIHR Doctoral Research Fellowship in 2018 to undertake her PhD at Imperial College London, which she completed in 2021. Alongside this she worked as senior clinical trial statistician at ICTU. In 2021 Rachel moved to Queen Mary University of London as a Senior Lecturer in Medical Statistics before returning to Imperial College London in 2023 as a Senior Lecturer in Medical Statistics and Clinical Trials, and co-head of Statistics for ICTU.
Publications
Journals
Pourmir I, Nebbache R, Champiat S, et al., 2024, Reporting and analysis of immunotherapy trials adverse events: what is going wrong, how to do better?, Annals of Oncology, ISSN:0923-7534
Farooq HZ, Apea V, Kasadha B, et al., 2023, Study protocol: the ILANA study - exploring optimal implementation strategies for long-acting antiretroviral therapy to ensure equity in clinical care and policy for women, racially minoritised people and older people living with HIV in the UK - a qualitative multiphase longitudinal study design, Bmj Open, Vol:13, ISSN:2044-6055
Yoong J, Yuen KH, Molton JS, et al., 2023, Cost-minimization analysis of oral versus intravenous antibiotic treatment for Klebsiella pneumoniae liver abscess, Scientific Reports, Vol:13, ISSN:2045-2322, Pages:1-7
Junqueira DR, Zorzela L, Golder S, et al., 2023, CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomized trials., Journal of Clinical Epidemiology, Vol:158, ISSN:0895-4356, Pages:149-165
Edwards MR, Forbes G, Walker N, et al., 2023, Fluid Optimisation in Emergency Laparotomy (FLO-ELA) Trial: study protocol for a multi-centre randomised trial of cardiac output-guided fluid therapy compared to usual care in patients undergoing major emergency gastrointestinal surgery, Trials, Vol:24, ISSN:1745-6215